Morphic Therapeutic Revenue and Competitors
Estimated Revenue & Valuation
- Morphic Therapeutic's estimated annual revenue is currently $26.3M per year.
- Morphic Therapeutic received $80.0M in venture funding in September 2018.
- Morphic Therapeutic's estimated revenue per employee is $201,000
- Morphic Therapeutic's total funding is $134.5M.
Employee Data
- Morphic Therapeutic has 131 Employees.
- Morphic Therapeutic grew their employee count by 12% last year.
Morphic Therapeutic's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr. VP Finance & CAO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | SVP Regulatory Affairs & Quality | Reveal Email/Phone |
5 | SVP, Head Biology and Translational Sciences | Reveal Email/Phone |
6 | VP DMPK & Clin Pharm | Reveal Email/Phone |
7 | SVP, Technical Operations | Reveal Email/Phone |
8 | VP, Head Chemical Sciences | Reveal Email/Phone |
9 | General Counsel, Corporate Secretary and Chief Compliance Officer | Reveal Email/Phone |
10 | SVP Corporate Business Development | Reveal Email/Phone |
Morphic Therapeutic Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Morphic Therapeutic?
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$134.5M
Total Funding
131
Number of Employees
$26.3M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Morphic Therapeutic News
Biogen Inc, BioMAS Ltd, Factor Therapeutics Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Morphic Therapeutic Inc, SciFluor Life Sciences LLC, Vascular...
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic...
NeuroSense Therapeutics announced the FDA had cleared its IND for PrimeC, ... Morphic Therapeutic initiated the EMERALD1 Phase IIa trial of...
Praveen Tipirneni, CEO of Waltham-based Morphic Therapeutic, is taking flack for a cartoon he drew about the biotech industry that bears a ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.5M | 132 | -14% | N/A |
#2 | $27.9M | 133 | 0% | N/A |
#3 | $41.9M | 141 | 5% | N/A |
#4 | $17.5M | 147 | 34% | $333M |
#5 | $18.9M | 147 | 23% | $137.5M |
Morphic Therapeutic Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-07-01 | $51.5M | A | SR One | Article |
| 2018-09-26 | $80.0M | B | Omega Funds | Article |